The authors of the IMpower010 trial randomized about 1000 patients with resected stage IB (≥4 cm) -IIIA NSCLC to receive adjuvant immunotherapy with the anti-programmed death-ligand 1 (PDL-1) monoclonal antibody atezolizumab (1200 mg every 3 weeks for 16 cycles) or best supportive care after adjuvant platinum-based chemotherapy up to 4 cycles. Here, CD274 is linked to non-small cell lung carcinoma.